<DOC>
	<DOCNO>NCT01052883</DOCNO>
	<brief_summary>The purpose study compare drug level darunavir obtain administration single administration 800 mg tablet ( new formulation ) follow administration two 400 mg commercial tablet formulation administer fed fasted condition also take low-dose ritonavir . Darunavir market treatment HIV . The short-term safety tolerability darunavir follow administration single 800 mg dose darunavir give healthy volunteer take take low-dose ritonavir also assess .</brief_summary>
	<brief_title>TMC114-TiDP3-C182 - A Study Compare Oral Bioavailability 800 mg Prototype Tablet Formulation Darunivar ( DRV ) That 400 mg Commercial Tablet Formulation Presence Low Dose Ritonavir , Under Fasted Fed Conditions</brief_title>
	<detailed_description>This open label study , mean party include study doctor , healthy volunteer sponsor know time treatment group volunteer . This cross trial , mean every volunteer sequentially subject 2 different treatment . A total 32 healthy volunteer participate study . Volunteers divide 2 panel 16 volunteer . Volunteers Panel 1 randomly assign treatment sequence AB BA . Volunteers Panel 2 randomly assign treatment sequence CD DC . During treatment period 100 mg ritonavir ( rtv ) dose daily Day 1 Day 5 . In treatment A receive single dose darunavir ( DRV ) two 400 mg commercial formulation morning day 3 standard breakfast . In treatment B receive single dose darunavir ( DRV ) 800 mg new formulation morning Day 3 also fed condition . In treatment C receive single dose darunavir ( DRV ) two 400 mg commercial formulation morning day 3 fasted condition . In treatment D receive single dose darunavir ( DRV ) 800 mg new formulation morning day 3 also fasted condition . Treatment session organize 7 day treatment period . In session , extensive investigation level DRV rtv blood circulation plan . Levels DRV assess 15 different time point , i.e . administration DRV 0.5 , 1 , 1.5 , 2 , 2.5 , 3 , 4 , 5 , 6 , 9 , 12 , 24 , 48 72 hour intake DRV . Levels rtv assess 13 different time point , i.e . administration rtv Day 3 , 0.5 , 1 , 1.5 , 2 , 2.5 , 3 , 4 , 5 , 6 , 9 12 hour intake rtv day 3 administration rtv Day 4 . Standard Safety assessment ( blood biochemistry hematology , urine analysis , ECG , pulse rate blood pressure ) perform Day1 , 3 6 Treatment period . Two 400 mg DRV commercial tablet formulation ( F030 ) single dose Day 3 treatment A C ; 800 mg DRV new tablet formulation ( G002 ) single dose Day 3 treatment B D ; 100 mg rtv capsule daily Day 1 Day 5 . All intake oral .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<criteria>Nonsmoking , smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month prior selection Normal weight define Body Mass Index ( BMI , weight kg divide square height meter ) 18.0 30.0 kg/m2 , extremes include Use effective non hormonal birth control method , willing continue practice birth control method least 30 day end treatment period female volunteer childbearing potential Negative serum pregnancy test breast feed screen Able comply protocol requirement Healthy basis medical evaluation reveals absence clinically relevant abnormality include physical examination , medical history , electrocardiogram ( ECG ) , vital sign , result blood biochemistry , blood coagulation , hematology test urinalysis carry screen Positive HIV 1 HIV 2 test screening Hepatitis A , B C infection screen History significant skin disease , limited rash eruption , food allergy psoriasis Allergy , hypersensitivity intolerance DRV rtv History allergy drug , limit , sulphonamides penicillin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>TMC114-TiDP3-C182</keyword>
	<keyword>TMC114-C182</keyword>
	<keyword>TMC114</keyword>
	<keyword>HIV</keyword>
	<keyword>HIV Infections</keyword>
</DOC>